Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels

Cardiovasc Hematol Disord Drug Targets. 2017 Jul 4;17(1):24-27. doi: 10.2174/1871529X17666170201104158.


Aim: This study compared the hematopoietic capacities of erythropoietin (Epo) and antioxidant drug U-74389G, based on 2 preliminary studies. The provided results on hematocrit levels augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.

Materials and methods: Hematocrit levels were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.

Results: The first preliminary study of Epo non-significantly increased the hematocrit levels by 0.24%+1.38% (p-value=0.8586). The second preliminary study of U-74389G significantly raised the hematocrit levels by 3.16%+1.33% (p-value=0.0196). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has approximately 12.66-fold higher hematopoietic potency than Epo (p-value=0.0000).

Conclusion: The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000).

Keywords: Hypoxia; U-74389G; cytokine; erythropoietin; hematocrit levels; reoxygenation.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Disease Models, Animal
  • Erythropoietin / pharmacology
  • Erythropoietin / therapeutic use*
  • Female
  • Hematocrit*
  • Hematopoiesis / drug effects*
  • Humans
  • Hypoxia / blood
  • Hypoxia / complications
  • Hypoxia / drug therapy*
  • Male
  • Pregnatrienes / pharmacology
  • Pregnatrienes / therapeutic use*
  • Rats, Wistar
  • Reperfusion Injury / blood
  • Reperfusion Injury / complications
  • Reperfusion Injury / drug therapy*


  • Antioxidants
  • Pregnatrienes
  • Erythropoietin
  • U 74389F